secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0000950170-24-018436
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia reports Q4 net loss $132.2M; cash $1.0B; on track for Phase 3 NTLA-2001 in Q1 2024
--------------------------------------------------------------------------------

- Q4 2023 net loss $132.2M vs $113.4M YoY; R&D expenses rose $9.0M to $109.0M.
- Cash, equivalents and securities $1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.
- On track to dose first patient in Phase 3 MAGNITUDE trial (NTLA-2001) for ATTR cardiomyopathy in Q1 2024.
- Plan to initiate Phase 3 of NTLA-2002 for hereditary angioedema in 2H24; positive interim Phase 1 data published in NEJM.
- Expanding pipeline: Phase 1 for NTLA-3001 (AATD) expected in 2024; collaboration with ReCode for cystic fibrosis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/0000950170-24-018436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000095017024018436/ntla-20240222.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-018436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer